<p>Travere Therapeutics, Inc.（納斯達克代碼：TVTX - 獲取免費報告）的股票已被目前覆蓋該公司的十七家評級機構評定為 “適度買入”，MarketBeat.com 報道。一位投資分析師給予該股票賣出評級，三位給予持有評級，十三位給予買入評級。在過去一年中，發佈報告的經紀商對該股票的平均一年目標價為 38.7143 美元。</p>
<p>獲取 <strong>Travere Therapeutics</strong> 的提醒：</p>
<ul>
<li>3 家不被關注的醫療公司</li>
</ul>
<p>多家研究機構已對 TVTX 發佈報告。傑富瑞金融集團在 9 月 10 日的研究報告中將 Travere Therapeutics 的目標價設定為 35.00 美元。花旗集團在 10 月 31 日的研究報告中將 Travere Therapeutics 的目標價從 34.00 美元上調至 48.00 美元，並給予該公司 “買入” 評級。華爾街禪在週六的研究報告中將 Travere Therapeutics 的評級從 “買入” 上調至 “強力買入”。富國銀行在 9 月 11 日的研究報告中將 Travere Therapeutics 的目標價從 27.00 美元上調至 35.00 美元，並給予該公司 “增持” 評級。最後，Weiss Ratings 在 10 月 8 日的研究報告中重申了對 Travere Therapeutics 的 “賣出（e+）” 評級。</p>
<p><strong>獲取我們最新的 TVTX 股票報告</strong></p>
<h2>Travere Therapeutics 股票下跌 0.5%</h2>
<ul>
<li>Travere Therapeutics 在鼓舞人心的數據後仍在上升</li>
</ul>
<p>納斯達克 TVTX 週一開盤價為 34.83 美元。該公司的五十日移動平均價格為 32.08 美元，二百日移動平均價格為 22.92 美元。該股票的市值為 31.2 億美元，市盈率為-32.86，貝塔係數為 0.89。Travere Therapeutics 的五十二週低點為 12.91 美元，五十二週高點為 37.50 美元。該公司的債務與股本比率為 4.23，流動比率為 2.75，速動比率為 2.71。</p>
<p>Travere Therapeutics（納斯達克代碼：TVTX - 獲取免費報告）最近於 10 月 30 日發佈了季度財報。該公司報告季度每股收益為 0.28 美元，超出分析師一致預期的-0.31 美元，超出幅度為 0.59 美元。Travere Therapeutics 的股本回報率為-178.68%，淨利潤率為-20.32%。該公司在本季度的收入為 1.6486 億美元，而分析師預期為 1.0609 億美元。去年同期，該公司每股收益為-0.70 美元。Travere Therapeutics 的收入同比增長 162.1%。股票分析師預計 Travere Therapeutics 本財年的每股收益將為-1.4 美元。</p>
<h2>內部買賣</h2>
<p>在其他 Travere Therapeutics 的新聞中，首席會計官 Sandra Calvin 於 11 月 4 日以每股 36.00 美元的平均價格出售了 67,115 股股票，總價值為 2,416,140.00 美元。交易完成後，首席會計官直接持有該公司 48,545 股股票，價值約為 1,747,620 美元。這筆交易代表了他們持有股票的 58.03% 的減少。該交易已在向證券交易委員會提交的文件中披露，您可以通過此鏈接訪問。此外，首席執行官 Eric M. Dube 於 10 月 28 日以每股 30.38 美元的平均價格出售了 92,872 股 Travere Therapeutics 股票，總價值為 2,821,451.36 美元。出售後，首席執行官直接持有該公司 419,173 股股票，價值為 12,734,475.74 美元。這筆交易代表了他們持有股票的 18.14% 的減少。有關此銷售的更多詳細信息可在官方 SEC 披露中找到。內部人士在過去 90 天內出售了價值 7,910,972 美元的 243,368 股公司股票。內部人士持有公司股票的 4.06%。</p>
<h2>機構資金流入和流出</h2>
<p>多家大型投資者最近增加或減少了對 TVTX 的持股。Penn Capital Management Company LLC 在第三季度將其在 Travere Therapeutics 的持股增加了 39.7%。Penn Capital Management Company LLC 現在擁有 27,004 股該公司的股票，價值 645,000 美元，此前在上個季度增持了 7,680 股。CIBC Bancorp USA Inc. 在第三季度獲得了對 Travere Therapeutics 股票的新頭寸，價值 225,000 美元。PharVision Advisers LLC 在第三季度購買了對 Travere Therapeutics 股票的新股份，價值 210,000 美元。Voloridge Investment Management LLC 在第三季度將其在 Travere Therapeutics 的持股增加了 18.7%。Voloridge Investment Management LLC 現在擁有 883,672 股該公司的股票，價值 21,120,000 美元，此前在該期間增持了 139,018 股。最後，Quarry LP 在第三季度將其在 Travere Therapeutics 的持股增加了 113.7%。Quarry LP 現在擁有 14,960 股該公司的股票，價值 358,000 美元，此前在該期間增持了 7,960 股。</p>
<h2>Travere Therapeutics 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>Travere Therapeutics, Inc. 是一家生物製藥公司，致力於識別、開發和提供針對罕見腎臟和代謝疾病的治療方案。其產品包括 FILSPARI（sparsentan），這是一種每日一次的口服藥物，旨在針對 IgA 腎病（內皮素 1 和血管緊張素-II）疾病進展中的兩個關鍵通路；以及 Thiola 和 Thiola EC（tiopronin 片），用於治療胱氨酸尿症，這是一種罕見的遺傳性胱氨酸轉運障礙，導致尿液中胱氨酸水平升高和反覆腎結石的形成。</p>
<h2>推薦故事</h2>
<ul>
<li>我們更看好的五隻股票，而非 Travere Therapeutics</li>
<li>投資旅遊股票的好處</li>
<li>Dave &amp; Buster’s 在雙底突破後反轉正在進行中</li>
<li>最佳能源股票 - 現在值得購買的能源股票</li>
<li>3 只在 10 年期國債利率上升時值得購買的金融股票</li>
<li>3 只值得購買的醫療保健分紅股票</li>
<li>迪士尼的 10 億美元交易將其魔力帶入 OpenAI</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VFZUWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VFZUWA"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快的報道和公正的覆蓋。如對本故事有任何問題或意見，請發送至 contact@marketbeat.com.</em></p>
<h2>你現在應該投資 1,000 美元在 Travere Therapeutics 嗎？</h2>
<p>在你考慮 Travere Therapeutics 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Travere Therapeutics 並不在名單上。</p>
<p>雖然 Travere Therapeutics 目前在分析師中有中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

TVTX

<p>Travere Therapeutics, Inc.（納斯達克代碼：TVTX）獲得了 17 家券商的共識評級為 “適度買入”，平均目標價為 38.71 美元。分析師的評級各不相同，包括賣出、持有和買入。近期內部交易中，首席會計官和首席執行官進行了大量股票出售。機構投資者已調整了在該公司的持股，顯著增加了持倉並建立了新頭寸</p>

<p>Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX - Get Free Report) have been assigned a consensus rating of &#34;Moderate Buy&#34; from the seventeen ratings firms that are currently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, three have given a hold rating and thirteen have issued a buy rating on the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $38.7143.</p>
<div class="lb-trans"><p>Travere Therapeutics, Inc.（納斯達克代碼：TVTX - 獲取免費報告）的股票已被目前覆蓋該公司的十七家評級機構評定為 “適度買入”，MarketBeat.com 報道。一位投資分析師給予該股票賣出評級，三位給予持有評級，十三位給予買入評級。在過去一年中，發佈報告的經紀商對該股票的平均一年目標價為 38.7143 美元。</p>
</div><p>Get <strong>Travere Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Travere Therapeutics</strong> 的提醒：</p>
</div><ul>
<li>3 Under-the-Radar Healthcare Companies</li>
</ul>
<div class="lb-trans"><ul>
<li>3 家不被關注的醫療公司</li>
</ul>
</div><p>A number of research firms have issued reports on TVTX. Jefferies Financial Group set a $35.00 target price on Travere Therapeutics in a research note on Wednesday, September 10th. Citigroup raised their price target on shares of Travere Therapeutics from $34.00 to $48.00 and gave the company a &#34;buy&#34; rating in a research note on Friday, October 31st. Wall Street Zen upgraded shares of Travere Therapeutics from a &#34;buy&#34; rating to a &#34;strong-buy&#34; rating in a research report on Saturday. Wells Fargo &amp; Company increased their price objective on shares of Travere Therapeutics from $27.00 to $35.00 and gave the company an &#34;overweight&#34; rating in a research note on Thursday, September 11th. Finally, Weiss Ratings restated a &#34;sell (e+)&#34; rating on shares of Travere Therapeutics in a research report on Wednesday, October 8th.</p>
<div class="lb-trans"><p>多家研究機構已對 TVTX 發佈報告。傑富瑞金融集團在 9 月 10 日的研究報告中將 Travere Therapeutics 的目標價設定為 35.00 美元。花旗集團在 10 月 31 日的研究報告中將 Travere Therapeutics 的目標價從 34.00 美元上調至 48.00 美元，並給予該公司 “買入” 評級。華爾街禪在週六的研究報告中將 Travere Therapeutics 的評級從 “買入” 上調至 “強力買入”。富國銀行在 9 月 11 日的研究報告中將 Travere Therapeutics 的目標價從 27.00 美元上調至 35.00 美元，並給予該公司 “增持” 評級。最後，Weiss Ratings 在 10 月 8 日的研究報告中重申了對 Travere Therapeutics 的 “賣出（e+）” 評級。</p>
</div><p><strong>Get Our Latest Stock Report on TVTX</strong></p>
<div class="lb-trans"><p><strong>獲取我們最新的 TVTX 股票報告</strong></p>
</div><h2>Travere Therapeutics Stock Down 0.5%</h2>
<div class="lb-trans"><h2>Travere Therapeutics 股票下跌 0.5%</h2>
</div><ul>
<li>Travere Therapeutics Still On The Rise After Encouraging Data</li>
</ul>
<div class="lb-trans"><ul>
<li>Travere Therapeutics 在鼓舞人心的數據後仍在上升</li>
</ul>
</div><p>NASDAQ TVTX opened at $34.83 on Monday. The business has a fifty day moving average price of $32.08 and a two-hundred day moving average price of $22.92. The stock has a market capitalization of $3.12 billion, a PE ratio of -32.86 and a beta of 0.89. Travere Therapeutics has a fifty-two week low of $12.91 and a fifty-two week high of $37.50. The company has a debt-to-equity ratio of 4.23, a current ratio of 2.75 and a quick ratio of 2.71.</p>
<div class="lb-trans"><p>納斯達克 TVTX 週一開盤價為 34.83 美元。該公司的五十日移動平均價格為 32.08 美元，二百日移動平均價格為 22.92 美元。該股票的市值為 31.2 億美元，市盈率為-32.86，貝塔係數為 0.89。Travere Therapeutics 的五十二週低點為 12.91 美元，五十二週高點為 37.50 美元。該公司的債務與股本比率為 4.23，流動比率為 2.75，速動比率為 2.71。</p>
</div><p>Travere Therapeutics (NASDAQ:TVTX - Get Free Report) last posted its quarterly earnings results on Thursday, October 30th. The company reported $0.28 EPS for the quarter, topping analysts' consensus estimates of ($0.31) by $0.59. Travere Therapeutics had a negative return on equity of 178.68% and a negative net margin of 20.32%.The company had revenue of $164.86 million during the quarter, compared to analysts' expectations of $106.09 million. During the same quarter in the previous year, the firm earned ($0.70) EPS. Travere Therapeutics's revenue was up 162.1% on a year-over-year basis. Equities analysts expect that Travere Therapeutics will post -1.4 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Travere Therapeutics（納斯達克代碼：TVTX - 獲取免費報告）最近於 10 月 30 日發佈了季度財報。該公司報告季度每股收益為 0.28 美元，超出分析師一致預期的-0.31 美元，超出幅度為 0.59 美元。Travere Therapeutics 的股本回報率為-178.68%，淨利潤率為-20.32%。該公司在本季度的收入為 1.6486 億美元，而分析師預期為 1.0609 億美元。去年同期，該公司每股收益為-0.70 美元。Travere Therapeutics 的收入同比增長 162.1%。股票分析師預計 Travere Therapeutics 本財年的每股收益將為-1.4 美元。</p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>內部買賣</h2>
</div><p>In other Travere Therapeutics news, CAO Sandra Calvin sold 67,115 shares of the stock in a transaction dated Tuesday, November 4th. The stock was sold at an average price of $36.00, for a total value of $2,416,140.00. Following the completion of the transaction, the chief accounting officer directly owned 48,545 shares in the company, valued at approximately $1,747,620. This trade represents a 58.03% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities &amp; Exchange Commission, which can be accessed through this link. Also, CEO Eric M. Dube sold 92,872 shares of Travere Therapeutics stock in a transaction dated Tuesday, October 28th. The shares were sold at an average price of $30.38, for a total value of $2,821,451.36. Following the sale, the chief executive officer directly owned 419,173 shares in the company, valued at $12,734,475.74. The trade was a 18.14% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 243,368 shares of company stock worth $7,910,972 in the last ninety days. Insiders own 4.06% of the company's stock.</p>
<div class="lb-trans"><p>在其他 Travere Therapeutics 的新聞中，首席會計官 Sandra Calvin 於 11 月 4 日以每股 36.00 美元的平均價格出售了 67,115 股股票，總價值為 2,416,140.00 美元。交易完成後，首席會計官直接持有該公司 48,545 股股票，價值約為 1,747,620 美元。這筆交易代表了他們持有股票的 58.03% 的減少。該交易已在向證券交易委員會提交的文件中披露，您可以通過此鏈接訪問。此外，首席執行官 Eric M. Dube 於 10 月 28 日以每股 30.38 美元的平均價格出售了 92,872 股 Travere Therapeutics 股票，總價值為 2,821,451.36 美元。出售後，首席執行官直接持有該公司 419,173 股股票，價值為 12,734,475.74 美元。這筆交易代表了他們持有股票的 18.14% 的減少。有關此銷售的更多詳細信息可在官方 SEC 披露中找到。內部人士在過去 90 天內出售了價值 7,910,972 美元的 243,368 股公司股票。內部人士持有公司股票的 4.06%。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>機構資金流入和流出</h2>
</div><p>A number of large investors have recently added to or reduced their stakes in TVTX. Penn Capital Management Company LLC grew its holdings in Travere Therapeutics by 39.7% during the 3rd quarter. Penn Capital Management Company LLC now owns 27,004 shares of the company's stock worth $645,000 after acquiring an additional 7,680 shares during the last quarter. CIBC Bancorp USA Inc. acquired a new position in shares of Travere Therapeutics during the third quarter worth $225,000. PharVision Advisers LLC bought a new stake in shares of Travere Therapeutics in the third quarter worth $210,000. Voloridge Investment Management LLC increased its holdings in Travere Therapeutics by 18.7% in the third quarter. Voloridge Investment Management LLC now owns 883,672 shares of the company's stock valued at $21,120,000 after purchasing an additional 139,018 shares during the period. Finally, Quarry LP increased its holdings in Travere Therapeutics by 113.7% in the third quarter. Quarry LP now owns 14,960 shares of the company's stock valued at $358,000 after purchasing an additional 7,960 shares during the period.</p>
<div class="lb-trans"><p>多家大型投資者最近增加或減少了對 TVTX 的持股。Penn Capital Management Company LLC 在第三季度將其在 Travere Therapeutics 的持股增加了 39.7%。Penn Capital Management Company LLC 現在擁有 27,004 股該公司的股票，價值 645,000 美元，此前在上個季度增持了 7,680 股。CIBC Bancorp USA Inc. 在第三季度獲得了對 Travere Therapeutics 股票的新頭寸，價值 225,000 美元。PharVision Advisers LLC 在第三季度購買了對 Travere Therapeutics 股票的新股份，價值 210,000 美元。Voloridge Investment Management LLC 在第三季度將其在 Travere Therapeutics 的持股增加了 18.7%。Voloridge Investment Management LLC 現在擁有 883,672 股該公司的股票，價值 21,120,000 美元，此前在該期間增持了 139,018 股。最後，Quarry LP 在第三季度將其在 Travere Therapeutics 的持股增加了 113.7%。Quarry LP 現在擁有 14,960 股該公司的股票，價值 358,000 美元，此前在該期間增持了 7,960 股。</p>
</div><h2>Travere Therapeutics Company Profile</h2>
<div class="lb-trans"><h2>Travere Therapeutics 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.</p>
<div class="lb-trans"><p>Travere Therapeutics, Inc. 是一家生物製藥公司，致力於識別、開發和提供針對罕見腎臟和代謝疾病的治療方案。其產品包括 FILSPARI（sparsentan），這是一種每日一次的口服藥物，旨在針對 IgA 腎病（內皮素 1 和血管緊張素-II）疾病進展中的兩個關鍵通路；以及 Thiola 和 Thiola EC（tiopronin 片），用於治療胱氨酸尿症，這是一種罕見的遺傳性胱氨酸轉運障礙，導致尿液中胱氨酸水平升高和反覆腎結石的形成。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推薦故事</h2>
</div><ul>
<li>Five stocks we like better than Travere Therapeutics</li>
<li>Investing in Travel Stocks Benefits</li>
<li>Dave &amp; Buster’s Reversal Is in PLAY After Double-Bottom Breakout</li>
<li>Best Energy Stocks - Energy Stocks to Buy Now</li>
<li>3 Finance Stocks to Buy on Rising 10-Year Treasury Rates</li>
<li>3 Healthcare Dividend Stocks to Buy</li>
<li>Disney's $1 Billion Deal Brings Its Magic to OpenAI</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，而非 Travere Therapeutics</li>
<li>投資旅遊股票的好處</li>
<li>Dave &amp; Buster’s 在雙底突破後反轉正在進行中</li>
<li>最佳能源股票 - 現在值得購買的能源股票</li>
<li>3 只在 10 年期國債利率上升時值得購買的金融股票</li>
<li>3 只值得購買的醫療保健分紅股票</li>
<li>迪士尼的 10 億美元交易將其魔力帶入 OpenAI</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VFZUWA" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=TVTX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快的報道和公正的覆蓋。如對本故事有任何問題或意見，請發送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Travere Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Travere Therapeutics 嗎？</h2>
</div><p>Before you consider Travere Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 Travere Therapeutics 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Travere Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Travere Therapeutics 並不在名單上。</p>
</div><p>While Travere Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Travere Therapeutics 目前在分析師中有中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Travere Therapeutics, Inc.（納斯達克股票代碼：TVTX）被券商給予平均評級為 “適度買入”